Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06342440 · ClinicalTrials.gov registry record
Early Detection of Advanced Adenomas and Colorectal Cancer
A clinical trial of Colorectal Cancer and Colorectal Neoplasms, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 6
- Study locations
NCT06342440: Recruiting study of Colorectal Cancer and Colorectal Neoplasms, sponsored by City of Hope Medical Center.
NCT06342440 is a study of Colorectal Cancer and Colorectal Neoplasms that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 2,000 participants, above the 1,539-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (30% higher). The trial reports 6 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06342440, a study of Colorectal Cancer and Colorectal Neoplasms, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.
Primary Outcome
True positive rate: the probability of a positive test result, conditioned on the individual truly being positive
Conditions Studied
Interventions
- DIAGNOSTIC_TEST DENEB
Study Locations (6)
Other
- The First Affiliated Hospital of Dalian Medical University - Dalian
- IRCCS San Raffaele - Milan
- Mie University - Mie
- Barcelona University - Barcelona
California
- City of Hope Medical Center - Monrovia
- University of California San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2020-03-15 |
| Est. Completion | 2026-06-18 |
What NCT06342440 shows while recruiting
NCT06342440 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,539-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (30% higher).
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which DENEB is the first listed.
NCT06342440 lists 6 locations in 2 states (Other, California).
Frequently Asked Questions
What is clinical trial NCT06342440 about?
NCT06342440 is a clinical study titled "Early Detection of Advanced Adenomas and Colorectal Cancer". This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.
What is the current status of trial NCT06342440?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2020-03-15. Estimated completion is 2026-06-18.
What conditions does trial NCT06342440 study?
This clinical trial studies the following conditions: Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Disorders, Colorectal Cancer Stage II.
What interventions are being tested in trial NCT06342440?
The interventions under investigation include: DENEB (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06342440?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06342440 being conducted?
This trial has 6 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06342440's enrollment target sits among peer trials
2,000 31st of 381 higher than 350 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI